Coherus BioSciences (CHRS) Narrows Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Coherus BioSciences (CHRS) Narrows Q4 Loss
March 23, 2015 4:00 PM EDT
REDWOOD CITY, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.
2014 Highlights:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): completed Phase 1 351(a) (novel biologic) study and transitioning to a 351(k) (biosimilar) approval pathway. In March 2015, the Company initiated a pivotal study, which, if positive, could support the filing of a 351(k) biologics license application (BLA) in the fourth quarter of 2015 or first quarter of 2016. An additional...
More
March 23, 2015 4:00 PM EDT
REDWOOD CITY, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.
2014 Highlights:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): completed Phase 1 351(a) (novel biologic) study and transitioning to a 351(k) (biosimilar) approval pathway. In March 2015, the Company initiated a pivotal study, which, if positive, could support the filing of a 351(k) biologics license application (BLA) in the fourth quarter of 2015 or first quarter of 2016. An additional...
More
March 23, 2015 4:00 PM EDT
REDWOOD CITY, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.
2014 Highlights:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar): completed Phase 1 351(a) (novel biologic) study and transitioning to a 351(k) (biosimilar) approval pathway. In March 2015, the Company initiated a pivotal study, which, if positive, could support the filing of a 351(k) biologics license application (BLA) in the fourth quarter of 2015 or first quarter of 2016. An additional...
More
